Connection

MITCHELL FREDERICK to Signal Transduction

This is a "connection" page, showing publications MITCHELL FREDERICK has written about Signal Transduction.
Connection Strength

0.633
  1. NOTCH1 Signaling in Head and Neck Squamous Cell Carcinoma. Cells. 2020 12 12; 9(12).
    View in: PubMed
    Score: 0.278
  2. Phosphoproteomic analysis of signaling pathways in head and neck squamous cell carcinoma patient samples. Am J Pathol. 2011 Feb; 178(2):548-71.
    View in: PubMed
    Score: 0.140
  3. Chk1/2 inhibition overcomes the cisplatin resistance of head and neck cancer cells secondary to the loss of functional p53. Mol Cancer Ther. 2013 Sep; 12(9):1860-73.
    View in: PubMed
    Score: 0.042
  4. Src inhibitors in suppression of papillary thyroid carcinoma growth. Head Neck. 2014 Mar; 36(3):375-84.
    View in: PubMed
    Score: 0.041
  5. Bypassing cisplatin resistance in Nrf2 hyperactivated head and neck cancer through effective PI3Kinase targeting. Br J Cancer. 2025 Dec; 133(12):1802-1814.
    View in: PubMed
    Score: 0.024
  6. Nrf2 Hyperactivation as a Driver of Radiotherapy Resistance and Suppressed Antitumor Immunity in Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2025 Oct 01; 31(19):4184-4195.
    View in: PubMed
    Score: 0.024
  7. Polo-like kinase 1 inactivation enhances PI3K inhibition-mediated apoptosis of NOTCH1-mutant head and neck squamous cell carcinoma. Cancer Lett. 2025 Aug 10; 625:217814.
    View in: PubMed
    Score: 0.024
  8. Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2023 04 03; 29(7):1344-1359.
    View in: PubMed
    Score: 0.020
  9. PDK1 Mediates NOTCH1-Mutated Head and Neck Squamous Carcinoma Vulnerability to Therapeutic PI3K/mTOR Inhibition. Clin Cancer Res. 2019 06 01; 25(11):3329-3340.
    View in: PubMed
    Score: 0.015
  10. Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors. Cancer Lett. 2017 04 28; 392:71-82.
    View in: PubMed
    Score: 0.013
  11. HRAS mutations and resistance to the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in head and neck squamous cell carcinoma cells. Head Neck. 2014 Nov; 36(11):1547-54.
    View in: PubMed
    Score: 0.011
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.